Lasmiditan in Migraine Management: An Advanced Review of Its Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug Interaction Spectrum, and Regulatory Approval

Abstract

Purpose

This review offers an in-depth evaluation of Lasmiditan, a novel and selective 5-HT1F receptor agonist, representing a significant breakthrough in migraine pharmacotherapy. Unlike existing reviews, this article consolidates all critical aspects of Lasmiditan into a single, authoritative source encompassing both extensive literature analysis and original findings from our laboratory to provide researchers and clinicians with streamlined access to essential data and minimize the need for exhaustive literature searches.

Main Findings

The review provides a comprehensive assessment of Lasmiditan, highlighting its physicochemical properties, pharmacological profile, mechanism of action, clinical efficacy and safety, drug interactions, and emerging insights from cell line studies. Lasmiditan’s solubility influences its bioavailability and efficacy. It acts centrally without vascular constriction, unlike traditional therapies. Clinical trials confirm its rapid, effective migraine relief with mild side effects. Minimal drug interactions support its use in polypharmacy. Cell studies reveal its receptor activity and transport mechanisms, enhancing therapeutic understanding.

Conclusion

Lasmiditan represents a groundbreaking addition to migraine therapeutics, providing a targeted, non-vasoconstrictive alternative. Its safety, tolerability, and efficacy make it a strong alternative for patients unsuitable for traditional treatments, with ongoing research likely to expand its clinical relevance.

Keywords

5-HT_1F Receptor - Clinical efficacy - Migraine - Lasmiditan - Non-vasoconstriction - Non-Triptan Therapy

Publikationsverlauf

Eingereicht: 01. Juli 2025

Angenommen nach Revision: 24. August 2025

Artikel online veröffentlicht:
24. September 2025

• References

• 1 Szkutnik Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs—Lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics 2020; 12 (12) 1180
• 2 Guzel T, Mirowska-Guzel D. The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy. Molecules. 2022; 27 (05) 1680
• 3 Afrooghe A, Ahmadi E, Babaei M. et al. Lasmiditan ameliorates serotonergic itch in mice: possible involvement of 5-HT1F receptors. Naunyn Schmiedebergs Arch Pharmacol 2024; 398: 1535-1543
• 4 Nelson DL, Phebus LA, Johnson KW. et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist Lasmiditan. Cephalalgia 2010; 30 (10) 1159-1169
• 5 Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT1F receptor agonist Lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother 2017; 18 (13) 1409-1415
• 6 Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action–review of a selective 5-HT1F agonist. J Headache Pain 2020; 21 (01) 71
• 7 Lamb YN. Lasmiditan: First Approval. Drugs 2019; 79 (18) 1989-1996
• 8 Beauchene JK, Levien TL. Lasmiditan: acute migraine treatment without vasoconstriction. A review. J Pharm Technol 2021; 37 (05) 244-253
• 9 Curto M, Cipolla F, Cisale GY. et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother 2020; 21 (02) 147-153
• 10 Cohen ML, Johnson KW, Schenck KW, Phebus LA. Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia 1997; 17 (06) 631-638
• 11 Rubio-Beltran E, Labastida-Ramírez A, Haanes KA. et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol 2019; 176 (24) 4681-4695
• 12 Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA. et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 2020; 161 (05) 1092-1099
• 13 Vila-Pueyo M, Page K, Murdock PR. et al. The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: implications for migraine and cluster headache. Br J Pharmacol 2022; 179 (03) 358-370
• 14 Klein MT, Dukat M, Glennon RA, Teitler M. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther 2011; 337 (03) 860-867
• 15 Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL. Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol 1998; 352 (01) 117-124
• 16 Jaber SH, Rajab NA. Lasmiditan nanoemulsion based in situ gel intranasal dosage form: formulation, characterization and in vivo study. Farmacia 2023; 71 (06) 1241-1253
• 17 Luffer-Atlas D, Wilbraham D, Posada MM, Landry J, Tsai M, Pearlman EM. Investigation of the effect of lasmiditan on the pharmacokinetics of P-glycoprotein and breast cancer resistance protein substrates. J Clin Pharmacol 2024; 64 (01) 94-102
• 18 Bhatti N, Abhilasha P, Joseph G. Lasmiditan: A novel drug for the acute treatment of migraine. Health 2024; 4: 24-29
• 19 Anderson CC, Vander Pluym JH. Profile of lasmiditan in the acute treatment of migraine in adults: design, development, and place in therapy. Drug Des Devel Ther 2023; 17: 1979-1993
• 20 Komori M, Mimura H, Tsai M, Ozeki A, Takaichi G, Wilbraham D. Safety, tolerability, and pharmacokinetics of Lasmiditan in healthy Japanese and Caucasian subjects. Rinsho Jpn J Clin Pharmacol Ther 2020; 51 (03) 119-127
• 21 Wan X, Zhang S, Jiang C, Zhang H. Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database. Expert Opin Drug Saf 2024; 10: 1-11
• 22 National Library of Medicine. Study of lasmiditan in the acute treatment of migraine (NCT03009162) 2019 https://www.clinicaltrials.gov/ct2/show/NCT03009162?term=Lasmiditan&draw=2&rank=16 [Cited 2024 Nov.]
• 23 National Library of Medicine. Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function. 2019 https://www.clinicaltrials.gov/study/NCT03040479 [Cited 2024 Nov.]
• 24 Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol 2019; 15: 189-198
• 25 Clemow DB, Baygani SK, Hauck PM, Hultman CB. Lasmiditan in patients with common migraine comorbidities: A post hoc efficacy and safety analysis of two phase 3 randomized clinical trials. Curr Med Res Opin 2020; 36: 1791-1806
• 26 Laohapiboolrattana W, Jansem P, Anukoolwittaya P. et al. Efficacy of Lasmiditan, Rimegepant and Ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain 2024; 25: 194
• 27 Parikh S. Lasmiditan. In: Martelletti P, Edvinsson L, editors Novel Synthetic Drugs in Migraine. Headache. Springer; 2022. pp. 83-95
• 28 Yonpiam R, Gobbet J, Jadhav A, Desai K, Blakley B, Al-Dissi A. Vasoactive effects of acute ergot exposure in sheep. Toxins 2021; 13 (04) 291
• 29 Gaddam S. Lasmiditan, a novel abortive agent for migraine therapy – from triptans to ditans. Int J Pharm Sci Rev Res 2023; 80 (02) 144-151
• 30 Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 2018; 91 (24) 2222-2232
• 31 Brandes JL, Klise S, Krege JH. et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of Lasmiditan for acute treatment of migraine (the GLADIATOR study. Cephalalgia 2019; 39: 1343-1357
• 32 Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist Lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012; 13: 271-275
• 33 Ferrari MD, Färkkilä M, Reuter U. et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist Lasmiditan—a randomized proof-of-concept trial. Cephalalgia 2010; 30: 1170-1178
• 34 Färkkilä M, Diener HC, Géraud G. et al. Efficacy and tolerability of Lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomized, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012; 11: 405-413
• 35 Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res 2018; 11: 2221-2227
• 36 Goadsby PJ, Wietecha LA, Dennehy EB. et al. Phase 3 randomized, placebo-controlled, double-blind study of Lasmiditan for acute treatment of migraine. Brain 2019; 142 (07) 1894-1904
• 37 Shapiro RE, Hochstetler HM, Dennehy EB. et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 2019; 20 (01) 90
• 38 Lipton RB, Lombard L, Ruff DD. et al. Trajectory of migraine-related disability following long-term treatment with Lasmiditan: results of the GLADIATOR study. J Headache Pain 2020; 21: 20
• 39 Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K. Sustained responses to Lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia 2019; 39: 1569-1576
• 40 Ashina M, Reuter U, Smith T. et al. Randomized, controlled trial of Lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia 2021; 41: 294-304
• 41 Krege JH, Rizzoli PB, Liffick E. et al. Safety findings from phase 3 Lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia 2019; 39 (08) 957-966
• 42 Pearlman EM, Wilbraham D, Dennehy EB. et al. Effects of Lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 2020; 35: 2732
• 43 Macone AE, Perloff MD. Lasmiditan: its development and potential use. Clin Pharmacol Drug Dev 2020; 9 (03) 292-296
• 44 Francescangeli J, Karamchandani K, Powell M, Bonavia A. The serotonin syndrome: from molecular mechanisms to clinical practice. Int J Mol Sci 2019; 20: 2288
• 45 Tsai M, Case M, Ardayfio P, Hochstetler H, Wilbraham D. Effects of Lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol. Clin Pharmacol Drug Dev 2020; 9: 629-638
• 46 Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics 2018; 15: 291-303
• 47 Loo LS, Ailani J, Schim J. et al. Efficacy and safety of Lasmiditan in patients using concomitant migraine preventive medications: Findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain 2019; 20: 84
• 48 Berg PH, Wilbraham D, Tsai M. Effects of Lasmiditan when coadministered with sumatriptan: Results of a randomized, double-blind, crossover study in healthy subjects. Headache 2019; 59: 115
• 49 Wilbraham D, Lufer Atlas D, Tsai M. Multiple-ascending dose, safety, tolerability, pharmacokinetic, and drug-drug interaction study with Lasmiditan. Headache 2020; 60: 95-96